Doptelet
avatrombopag
APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaHematology
Launch2018-05-21
Peak Sales Est$2000M
Formulations[{"id":"doptelet-po-adult","doses":"20 mg once daily (ITP), 40-60 mg daily for 5 days pre-procedure
Mechanism: Thrombopoietin receptor agonist
Expert: Small molecule agonist of the thrombopoietin receptor, stimulating megakaryopoiesis
Everyday: Stimulates production of platelets
Targets: ["TPOR"]
Revenue History
| Period | Revenue ($M) |
|---|
| 2024 | $470M |
| Q4 2025 | $144M |
Programs (3)
| Indication | Stage | Key Study | Regional Status |
|---|
| Chronic ITP (adult) | APPROVED | Pivotal ITP trial | [{"stage":"APPROVED","region":"US","approval_date":"2019-06-21"},{"stage":"APPRO |
| Chronic ITP (pediatric) | APPROVED | Pediatric ITP trial | [{"notes":"Including new Sprinkle formulation for ages 1-6","stage":"APPROVED"," |
| CLD thrombocytopenia | APPROVED | ADAPT-1/2 | [{"stage":"APPROVED","region":"US","approval_date":"2018-05-21"}] |
Clinical Studies (2)
Primary EP: [{"id":"adapt1-ep1","name":"Proportion NOT requiring platelet transfusion or rescue for bleeding","type":"PRIMARY","p_value":"<0.0001 (both cohorts)","results":[{"n":"59/90","arm":"adapt1-60","label":
Safety: AE incidence similar between avatrombopag and placebo. No hepatotoxicity signal. No increase in thromboembolic events. No bleeding events increase. No rebound thrombocytopenia. Portal vein thrombosis:
Primary EP: [{"id":"dotp-itp-ep1","name":"Cumulative weeks of platelet response (>=50K) without rescue","type":"PRIMARY","unit":"weeks","p_value":"<0.0001","results":[{"arm":"dotp-itp","label":"12.4 weeks (median
Safety: Headache 37.5% (vs 11.8% placebo). Contusion, URTI, arthralgia, epistaxis, fatigue, gingival bleeding, petechiae, nasopharyngitis all >=10%. No hepatotoxicity. Oral dosing with no food restriction.
Upcoming Catalysts (1)
Doptelet - Pediatric ITP + EU Expansion - Ongoing
H1 2026
Notes
Oral TPO receptor agonist for ITP and CLD thrombocytopenia. SOBI's biggest revenue drug. Pediatric ITP approved Jul 2025 (expanded TAM). Key differentiator vs Promacta (eltrombopag, NVS ~$2.2B 2024 sales): NO dietary restrictions (Promacta can't be taken with dairy/calcium/antacids), NO liver monitoring (Promacta requires monthly LFTs), comparable efficacy. Promacta going generic could pressure pricing but Doptelet's convenience advantage supports share gains. Acquired from Dova Pharmaceuticals.
Data from Supabase · Updated 2026-03-24